A three-year price record for the shares of the Hungarian pharmaceutical company Gedeon Richter was broken on Monday: the price rose above HUF 7,300 at the Budapest Stock Exchange.
The company is one of the winners of the coronavirus epidemic, it is helped by the weakening of the Hungarian currency, and its sales are not affected by the crisis, in fact, cariprazine is doing particularly well.
"In the current crisis, pharmaceutical companies have remained pillars of stability. Richter has also done well this year. Its generic pharmaceutical portfolio has remained stable in the COVID crisis and has even grown since it was not affected by the crisis. The U.S. sales of [another Richter product,] the Allergan have also been rising for several quarters, the company reports record sales data," Attila Gajdács, equity analyst at OTP Fund Management told the business site napi.hu
Top 5 Articles
Duna House Profit Climbs Nearly 70% in Q3 November 24, 2025 
'Recharge' Campaign Launched to Boost Domestic Tourism January 21, 2026 
Richter Earnings Slip as Financial Loss Weighs November 6, 2025 
Asiana Airlines to Launch Direct Seoul-Budapest Flight October 31, 2025 
Genius Automotive Hungarian Subsidiary's CEE Expansion November 2, 2025
